The effects of psychotomimetics and psychomotor stimulants on two schedules promoting response switching in the rat

Abstract Rationale. Psychosis and psychotomimetic drugs result in a disorganisation of the structure of thought and behaviour. Normalising these is one of the objects of antipsychotic therapy, and methods for predicting such a therapeutic effect would be of value. Objective. The effects of a number of psychotomimetic agents were examined on the way in which rats distributed responding over two response levers using two different procedures, to assay their effects on behavioural organisation. Previously, amphetamine has been found to increase response switching using these schedules. Methods. In the first, the random reinforcement procedure, one of the two levers was selected at random as "correct", and responses on this lever were reinforced with food under a random ratio schedule. No signal was given to distinguish the levers. Responding could also result in the food tray being illuminated, but no food pellet was delivered ("no-food" event). Responses on the second lever ("incorrect") had no programmed consequences. After each food delivery or "no-food" event the levers designated as "correct" and "incorrect" were reassigned at random, and the rat had to open the food tray to restart the schedule. In the second procedure, the rats were required to make 21 responses before a switch between the two levers resulted in food delivery [Fixed Ratio (FR) 21-switch]. The responses making up the FR could be distributed freely between the two levers. Results. Phencyclidine (PCP), scopolamine, caffeine and ethanol increased switching under the random reinforcement procedure, but (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) and atropine did not. PCP, caffeine, lysergic acid diethylamide (LSD) and atropine increased switching under the FR21-switch procedure, but ethanol did not. The increases in switching produced by PCP, LSD and the anticholinergics were accompanied by marked reductions in response rate, whereas those produced by amphetamine and caffeine were not. The effects of amphetamine, and PCP were strongly dependent on the baseline probability of switching, those of atropine and caffeine moderately so, and those of LSD and ethanol only weakly so. Conclusions. Of the agents tested, psychomotor stimulants appear to produce the most selective increases in switching. The procedures described here may be useful for assaying the disorganisation of behaviour produced by other psychotomimetics and may have value in the detection of novel antipsychotic drugs. Electronic Publication     

大鼠肺孢子虫肺炎肺脏病理学变化的动态研究

目的研究大鼠肺孢子虫肺炎（PCP）不同病程的动态病理学变化。方法将雌性清洁级SD大鼠50只随机分成实验组和对照组，每组25只。实验组采用皮下注射地塞米松1mg／只／次、每周2次免疫抑制的方法诱导建立PCP的动物模型，对照组则注射相同剂量的灭菌生理盐水。在所有大鼠的饮水中加入1g／L盐酸四环素预防继发性细菌感染。免疫抑制3、5、7、9、11周后．每组各取5只大鼠进行解剖，分别制作肺组织印片，姬氏染色，检香肺孢子虫包囊，同时制作肺组织病理切片，HE染色，观察肺组织的病理学变化。结果用地塞米松诱导大鼠3周，其肺组织印片术查见肺孢子虫包囊，肺组织也未见明显的病理学改变；第5周，肺组织印片州均查见肺孢予虫包囊，肺组织出现病理学改变。并且病理学孜变随诱导时间的增加而加重；第7周主要表现为肺泡壁毛细血管轻度充血，间质内慢性炎性细胞浸润；至第9周至11周，则可见间质细胞增生、间质水肿、肺泡内出现粉红色泡沫样渗出物，部分肺组织呈现大片状实变区。对照组大鼠无异常表现，病原学检查阴性，肺脏组织无明显的病理学改变。结论应用皮下注射地塞米松免疫抑制诱导方法可成功建立肺孢子虫肺炎的大鼠实验模型，大鼠肺孢子虫肺炎的病理学改变以炎症、渗出、细胞浸润、间质细胞增生等为主．同时病理学改变随病程进展而加重。     

Use of the fluorescent probe 1-anilino-8-naphthalene sulfonate to monitor the interactions of chlorophenols with phospholipid membranes (liposomes)

The fluorescence intensity (F₄₈₀), at pH 8, of 1-anilino-8-naphthalene sulfonate (ANS) bound to phospholipid membranes (liposomes) was decreased in the presence of mono-, di- and pentachlorophenols (pesticides and chemical intermediates that are toxic to animals). No shifts in emission spectra occurred, and no decreases in ANS fluorescence intensity were observed, in the presence of chlorophenols if liposomes were absent. An exception was 2,6-dichlorophenol which, at pH 8, had no effect on membrane-bound ANS-F₄₈₀. Using liposomes prepared from dimyristoyl lecithin, a 50 per cent decrease in membrane-bound ANS-F₄₈₀ was produced by 0.046 mM pentachlorophenol and 0.2–0.5 mM dichlorophenols (excluding the 2,6-derivative). These results are consistent with published toxicological data on polychlorinated phenols that show an order of toxicity: pentachlorophenol > 2,4-dichlorophenol > 2,6-dichlorophenol.     

Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys

Rationale Prepulse inhibition (PPI) of the acoustic startle reflex is a measure of sensorimotor gating, which occurs across species and is deficient in severe neuropsychiatric disorders such as schizophrenia. In monkeys, as in rodents, phencyclidine (PCP) induces schizophrenia-like deficits in PPI. In rodents, in general, typical antipsychotics (e.g. haloperidol) reverse PPI deficits induced by dopamine (DA) agonists (e.g. apomorphine), but not those induced by N-methyl-d-aspartate (NMDA) receptor antagonists [e.g. phencyclidine (PCP)], whereas atypical antipsychotics (e.g. clozapine) reverse PPI deficits induced by DA agonists and NMDA antagonists. However, some discrepancies exist with some compounds and strains of rodents.Objectives This study investigated whether a typical (haloperidol, 0.035 mg/kg) and an atypical (clozapine, 2.5 mg/kg) antipsychotic could be distinguished in their ability to reverse PCP-induced deficits in PPI in eight monkeys (Cebus apella).Methods First, haloperidol dose was determined by its ability to attenuate apomorphine-induced deficits in PPI. Then, haloperidol and clozapine were tested in eight monkeys with PCP-induced deficits of PPI. Experimental parameters were similar to standard human PPI procedures, with 115 dB white noise startle pulses, either alone or preceded by 120 ms with a prepulse 16 dB above the 70 dB background noise.Results Clozapine reversed PCP-induced PPI deficits. In contrast, haloperidol did not significantly attenuate PCP-induced PPI deficits even at doses that significantly attenuated apomorphine effects.Conclusions In this primate model, clozapine was distinguishable from haloperidol by its ability to attenuate PCP-induced deficits in PPI. The results provide further evidence that PPI in nonhuman primates may provide an important animal model for the development of novel anti-schizophrenia medications.     

Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies

In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs (miRNAs) in the pathophysiology of major depressive disorder (MDD) and the use of small RNAs (e.g.., small interfering RNAs or siRNAs) to knockdown genes in monoaminergic and non-monoaminergic neurons and induce antidepressant-like responses in experimental animals.The development of glutamatergic agents is a promising venue for antidepressant drug development, given the antidepressant properties of the non-competitive NMDA receptor antagonist ketamine. Its unique properties appear to result from the activation of AMPA receptors by a metabolite [(2 S,6 S;2 R,6 R)-hydroxynorketamine (HNK)] and mTOR signaling. These effects increase synaptogenesis in prefrontal cortical pyramidal neurons and enhance serotonergic neurotransmission via descending inputs to the raphe nuclei. This view is supported by the cancellation of ketamine's antidepressant-like effects by inhibition of serotonin synthesis.We also review existing evidence supporting the involvement of miRNAs in MDD and the preclinical use of RNA interference (RNAi) strategies to target genes involved in antidepressant response. Many miRNAs have been associated to MDD, some of which e.g., miR-135 targets genes involved in antidepressant actions. Likewise, SSRI-conjugated siRNA evokes faster and/or more effective antidepressant-like responses. Intranasal application of sertraline-conjugated siRNAs directed to 5-HT_1A receptors and SERT evoked much faster changes of pre- and postsynaptic antidepressant markers than those produced by fluoxetine.     

Acquisition of oral phencyclidine (PCP) self-administration in rhesus monkeys: effects of dose and an alternative non-drug reinforcer

 The effects of drug dose and a non-drug alternative reinforcer on acquisition of oral PCP self-administration in rhesus monkeys were examined. Acquisition was studied using three groups of monkeys (seven subjects per group). One group received a low PCP dose (0.0375 mg/delivery) and the other two received a high PCP dose (0.15 mg/delivery). One of the high dose groups had concurrent access to a saccharin solution (0.03% w/v) and water during the intersession (17.5-h) period. Food non-restricted monkeys were initially given access to water under a fixed-ratio (FR) 1 schedule during daily 3-h sessions. Water was then replaced with PCP during the session. The monkeys were then reduced to 85% of their free-feeding body weights and fed before the session, and the FR value was increased from 1 to 2, 4 and 8. Subsequently, food was given post-session and water and PCP were available under concurrent FR 8 schedules. At this final step of the procedure, acquisition of PCP self-administration was considered to occur if PCP intake consistently exceeded water intake. When all three groups were given concurrent access to PCP and water, PCP intake was greater than water intake only in the group of monkeys receiving the high PCP dose. PCP intake increased when water replaced saccharin during intersession in the high PCP dose group. Within-group data revealed that 85.7% of monkeys acquired PCP reinforcement in the group given access to the high PCP dose while only 42.8% acquired in the other two groups. These data suggest that drug dose and presence of alternative non-drug reinforcers affect acquisition of drug self administration in non-human primates. Received: 14 May 1997 / Final version: 15 December 1997     

Phencyclidine (PCP) receptors: autoradiographic localization in brain with the selective ligand, [H]TCP

Receptor binding sites for the phencyclidine (PCP) analogue, [³H]TCP, have been localized in the rat and guinea pig central nervous systems by in vitro autoradiography. Quantitation of [³H]TCP binding site densities in rat brain reveals highest levels in the forebrain, in particular the strata oriens and radiatum of the hippocampus, the molecular layer of the dentate gyrus and superficial layers of the cerebral cortex. Moderate levels of binding occur in the amygdala, thalamus, anterior olfactory nucleus external plexiform layer of the olfactory bulb, olfactory tubercle, geniculate nuclei and deep layers of the cortex. Low levels of binding occur throughout most of the septum, diagonal band, hypothalamus, pons-medulla and cerebellum. Spinal cord grey matter also has low levels binding. Excitotoxin lesions of the hippocampal formation, which destroy the pyramidal and granule cells, reduce the binding of [³H]TCP to strata radiatum and oriens and the molecular layer of the dentage gyrus by 60% suggesting that [³H]TCP labels intrinsic neurons in these regions. Residual binding is probably on afferent terminals. Ibotenic acid lesions of the caudate-putamen reduce [³H]TCP binding by 70%, indicating that binding sites are localized on intrinsic striatal neurons. 6-Hydroxydopamine lesions do not alter [³H]TCP binding levels the caudate, suggesting the absence of binding sites on dopaminergic terminals in the caudate.     

Wnt11r is required for cranial neural crest migration

wnt11r is a recently identified member of the Wnt family of genes, which has been proposed to be the true Xenopus homologue to the mammalian wnt11 gene. In this study we have examined the role of wnt11r on neural crest development. Expression analysis of wnt11r and comparison with the neural crest marker snail2 and the noncanonical Wnt, wnt11, shows wnt11r is expressed at the medial or neural plate side of the neural crest while wnt11 is expressed at the lateral or epidermal side. Injection of wnt11r morpholino leads to strong inhibition of neural crest migration with no effect on neural crest induction or maintenance. This effect can be rescued by co‐injection of Wnt11r but not by Wnt11 mRNA, demonstrating the specificity of the loss of function treatment. Finally, neural crest graft experiments show that wnt11r is required in a non–cell‐autonomous manner to control neural crest migration. Developmental Dynamics 237:3404–3409, 2008. © 2008 Wiley‐Liss, Inc.     

Pharmacological regulation of the phencyclidine-binding site associated with the N-methyl-D-Aspartate receptor-operated ion channel

The ion channel operated by N-methyl-D-aspartate (NMDA) receptor agonists is modified by several positive and negative effectors. A variety of chemical structures are known to antagonize the effects of NMDA agonists by preferentially binding with high affinity to the open state of the ion channel. Binding of two of these noncompetitive antagonists has been study extensively in recent months as a probe of NMDA receptor function. It has been found that NMDA agonists and antagonists increase and decrease, respectively, the binding of ³H-TCP or ³H-MK-801 by altering the affinity of the putative phencyclidine (PCP) receptor localized within the ion channel. This affinity change is presumed to be correlated with the conformational change associated with channel opening. This model is also discussed in relationship to one in which binding is increased under nonequilibrium conditions because of a simple increased accessibility to the channel binding site. The modulatory effects of glycine, other amino acids, certain polyamines, and divalent cations on ³H-TCP and/or ³H-MK-801 binding are discussed in relation to their effects on NMDA function in more intact, physiological preparations. It is concluded that the complexity of NMDA receptor regulation provides many possibilities for pharmacological intervention, and that the use of noncompetitive antagonists to probe NMDA receptor function could play a key role in drug development.